Seeking Alpha EN

Theriva Biologics GAAP EPS of -$2.08

Mar 12, 2026 &03121212202631; 19:12 UTC seekingalpha.com Trending 2/5

Read original on seekingalpha.com ↗

↘

Negative for markets

Sentiment score: -75/100

High impact Immediate effect (hours)

WHAT THIS MEANS

Theriva Biologics reported a significant GAAP loss per share of -$2.08, indicating substantial operational losses and negative earnings. This reflects ongoing challenges in the biotech company's path to profitability and cash burn concerns.

AI CONFIDENCE

85% Very high

SENTIMENT GAUGE

NEWS POWER SCORE

AFFECTED ASSETS

↓

THRB

THRBStock

Expected to decline

Significant negative EPS of -$2.08 indicates substantial losses, likely to trigger selling pressure and concern about cash runway and path to profitability

PRICE HISTORY

Loading chart...

⚡ SUGGESTED ACTION

Avoid or reduce exposure to THRB. Monitor cash position and upcoming financing announcements closely. Consider shorting if technical resistance breaks, but be cautious of biotech volatility and potential clinical trial catalysts that could reverse sentiment.

KEY SIGNALS

Large negative EPS signals ongoing cash burnBiotech company struggling with profitabilityPotential liquidity concerns aheadRisk of dilution through future financing

SECTORS INVOLVED

BiotechnologyHealthcareLife Sciences

Analysis generated on Mar 16, 2026 at 16:30 UTC

Disclaimer: This analysis is generated by artificial intelligence for informational purposes only and does not constitute financial advice, investment recommendation, or solicitation. Original reporting by Seeking Alpha. Always conduct your own research and consult a qualified financial advisor before making investment decisions.

Theriva Biologics GAAP EPS of -$2.08

RELATED INTELLIGENCE